Header Logo

Connection

Chad Hamilton to Humans

Back to Details
This is a "connection" page, showing publications Chad Hamilton has written about Humans.
Chad Hamilton
Connection Strength
0.880
Humans
  1. Lipoma or Liposarcoma? Robotic Resection of a Retroperitoneal Mass. J Obstet Gynaecol Can. 2022 10; 44(10):1095-1096.e1.
    View in: PubMed
    Score: 0.044
  2. Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations. Gynecol Oncol. 2021 03; 160(3):817-826.
    View in: PubMed
    Score: 0.042
  3. Endometrial cancer: A society of gynecologic oncology evidence-based review and recommendations, part II. Gynecol Oncol. 2021 03; 160(3):827-834.
    View in: PubMed
    Score: 0.042
  4. Gynecologic Oncology in the Department of Defense. Semin Reprod Med. 2019 09; 37(5-06):222-226.
    View in: PubMed
    Score: 0.040
  5. Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study. Gynecol Oncol. 2018 02; 148(2):275-280.
    View in: PubMed
    Score: 0.034
  6. Survival advantage of marriage in uterine cancer patients contrasts poor outcome for widows: a Surveillance, Epidemiology and End Results study. Gynecol Oncol. 2015 Feb; 136(2):328-35.
    View in: PubMed
    Score: 0.028
  7. Pyocolpos presenting as a large pelvic mass after total colpocleisis. Am J Obstet Gynecol. 2015 Jan; 212(1):113.e1-2.
    View in: PubMed
    Score: 0.027
  8. Atypical ovarian calcifications associated with bilateral borderline ovarian tumors. J Ultrasound Med. 2013 Jun; 32(6):1059-61.
    View in: PubMed
    Score: 0.025
  9. Growing teratoma syndrome: Brief communication and algorithm for management. Aust N Z J Obstet Gynaecol. 2013 Jun; 53(3):318-21.
    View in: PubMed
    Score: 0.025
  10. The impact of disease distribution on survival in patients with stage III epithelial ovarian cancer cytoreduced to microscopic residual: a Gynecologic Oncology Group study. Gynecol Oncol. 2011 Sep; 122(3):521-6.
    View in: PubMed
    Score: 0.022
  11. Gemcitabine-associated large vessel vasculitis presenting as fever of unknown origin. J Clin Rheumatol. 2010 Jun; 16(4):181-2.
    View in: PubMed
    Score: 0.020
  12. Intraperitoneal bevacizumab for the palliation of malignant ascites in refractory ovarian cancer. Gynecol Oncol. 2008 Dec; 111(3):530-2.
    View in: PubMed
    Score: 0.018
  13. Benign disorders of the ovary. Obstet Gynecol Clin North Am. 2008 Jun; 35(2):271-84, ix.
    View in: PubMed
    Score: 0.018
  14. Clinical aspects of uterine papillary serous carcinoma. Curr Opin Obstet Gynecol. 2008 Feb; 20(1):26-33.
    View in: PubMed
    Score: 0.017
  15. Acute postoperative thrombotic thrombocytopenic purpura following hysterectomy and lymphadenectomy for endometrial cancer. Gynecol Oncol. 2007 Aug; 106(2):423-6.
    View in: PubMed
    Score: 0.016
  16. Intraperitoneal chemotherapy for ovarian cancer. Curr Opin Oncol. 2006 Sep; 18(5):507-15.
    View in: PubMed
    Score: 0.016
  17. The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma. Gynecol Oncol. 2006 Nov; 103(2):679-83.
    View in: PubMed
    Score: 0.015
  18. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006 Mar 13; 94(5):642-6.
    View in: PubMed
    Score: 0.015
  19. Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma. Int J Radiat Oncol Biol Phys. 2005 Nov 01; 63(3):839-44.
    View in: PubMed
    Score: 0.015
  20. Factors Associated With Survival Disparities Between Non-Hispanic Black and White Patients With Uterine Cancer. JAMA Netw Open. 2023 04 03; 6(4):e238437.
    View in: PubMed
    Score: 0.012
  21. Conditional estimates for uterine serous cancer: Tools for survivorship counseling and planning. Gynecol Oncol. 2022 07; 166(1):90-99.
    View in: PubMed
    Score: 0.012
  22. Proteogenomic landscape of uterine leiomyomas from hereditary leiomyomatosis and renal cell cancer patients. Sci Rep. 2021 04 30; 11(1):9371.
    View in: PubMed
    Score: 0.011
  23. Is imaging at intermediate doses necessary during dobutamine stress magnetic resonance imaging? J Cardiovasc Magn Reson. 2001; 3(4):297-302.
    View in: PubMed
    Score: 0.011
  24. Results of an early safety analysis of a study of the combination of pembrolizumab and pelvic chemoradiation in locally advanced cervical cancer. Cancer. 2020 11 15; 126(22):4948-4956.
    View in: PubMed
    Score: 0.010
  25. Minority participation in phase 1 gynecologic oncology clinical trials: Three decades of inequity. Gynecol Oncol. 2020 06; 157(3):729-732.
    View in: PubMed
    Score: 0.010
  26. Racial disparities in uterine and ovarian carcinosarcoma: A population-based analysis of treatment and survival. Gynecol Oncol. 2020 04; 157(1):67-77.
    View in: PubMed
    Score: 0.010
  27. Impact of adjuvant treatment and prognostic factors in stage I uterine leiomyosarcoma patients treated in Commission on Cancer?-accredited facilities. Gynecol Oncol. 2020 04; 157(1):121-130.
    View in: PubMed
    Score: 0.010
  28. Jupiter microtubule-associated homolog 1 (JPT1): A predictive and pharmacodynamic biomarker of metformin response in endometrial cancers. Cancer Med. 2020 02; 9(3):1092-1103.
    View in: PubMed
    Score: 0.010
  29. Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study. Gynecol Oncol. 2020 01; 156(1):131-139.
    View in: PubMed
    Score: 0.010
  30. Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients. Cancer Med. 2019 08; 8(10):4678-4687.
    View in: PubMed
    Score: 0.009
  31. Biomarker panel for early detection of endometrial cancer in the Prostate, Lung, Colorectal, and Ovarian cancer screening trial. Am J Obstet Gynecol. 2019 11; 221(5):472.e1-472.e10.
    View in: PubMed
    Score: 0.009
  32. Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma. Obstet Gynecol. 2019 02; 133(2):245-254.
    View in: PubMed
    Score: 0.009
  33. Racial disparities in molecular subtypes of endometrial cancer. Gynecol Oncol. 2018 04; 149(1):106-116.
    View in: PubMed
    Score: 0.009
  34. Correlation between Surgeon's assessment and radiographic evaluation of residual disease in women with advanced stage ovarian cancer reported to have undergone optimal surgical cytoreduction: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2018 06; 149(3):525-530.
    View in: PubMed
    Score: 0.009
  35. Relative Effects of Age, Race, and Stage on Mortality in Gestational Choriocarcinoma. Int J Gynecol Cancer. 2018 02; 28(2):338-345.
    View in: PubMed
    Score: 0.009
  36. Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study. Gynecol Oncol. 2018 01; 148(1):49-55.
    View in: PubMed
    Score: 0.008
  37. Surgical outcomes among elderly women with endometrial cancer treated by laparoscopic hysterectomy: a NRG/Gynecologic Oncology Group study. Am J Obstet Gynecol. 2018 01; 218(1):109.e1-109.e11.
    View in: PubMed
    Score: 0.008
  38. Impact of age at diagnosis on racial disparities in endometrial cancer patients. Gynecol Oncol. 2018 04; 149(1):12-21.
    View in: PubMed
    Score: 0.008
  39. Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patients. Cancer. 2017 Oct 15; 123(20):4004-4012.
    View in: PubMed
    Score: 0.008
  40. Establishment and characterization of a platinum- and paclitaxel-resistant high grade serous ovarian carcinoma cell line. Hum Cell. 2017 Jul; 30(3):226-236.
    View in: PubMed
    Score: 0.008
  41. Interim analysis of a phase I/IIa trial assessing E39+GM-CSF, a folate binding protein vaccine, to prevent recurrence in ovarian and endometrial cancer patients. Oncotarget. 2017 Feb 28; 8(9):15912-15923.
    View in: PubMed
    Score: 0.008
  42. Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 04; 145(1):122-129.
    View in: PubMed
    Score: 0.008
  43. Progesterone potentiates the growth inhibitory effects of calcitriol in endometrial cancer via suppression of CYP24A1. Oncotarget. 2016 Nov 22; 7(47):77576-77590.
    View in: PubMed
    Score: 0.008
  44. What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study. Cancer. 2017 May 15; 123(6):985-993.
    View in: PubMed
    Score: 0.008
  45. Nestin suppression attenuates invasive potential of endometrial cancer cells by downregulating TGF-? signaling pathway. Oncotarget. 2016 Oct 25; 7(43):69733-69748.
    View in: PubMed
    Score: 0.008
  46. Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis. Gynecol Oncol. 2016 Dec; 143(3):460-465.
    View in: PubMed
    Score: 0.008
  47. Femoral artery occlusion following pelvic cancer surgery. Gynecol Oncol. 1996 Oct; 63(1):151-3.
    View in: PubMed
    Score: 0.008
  48. Progestins inhibit calcitriol-induced CYP24A1 and synergistically inhibit ovarian cancer cell viability: An opportunity for chemoprevention. Gynecol Oncol. 2016 10; 143(1):159-167.
    View in: PubMed
    Score: 0.008
  49. Does Routine Posttreatment PET/CT Add Value to the Care of Women With Locally Advanced Cervical Cancer? Int J Gynecol Cancer. 2016 06; 26(5):944-50.
    View in: PubMed
    Score: 0.008
  50. Nestin: A biomarker of aggressive uterine cancers. Gynecol Oncol. 2016 Mar; 140(3):503-11.
    View in: PubMed
    Score: 0.007
  51. Reply to G.D. Aletti et al. J Clin Oncol. 2015 Oct 20; 33(30):3521-2.
    View in: PubMed
    Score: 0.007
  52. Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patients. J Proteome Res. 2015 Apr 03; 14(4):1900-10.
    View in: PubMed
    Score: 0.007
  53. Proteomics of the human endometrial glandular epithelium and stroma from the proliferative and secretory phases of the menstrual cycle. Biol Reprod. 2015 Apr; 92(4):106.
    View in: PubMed
    Score: 0.007
  54. Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. J Clin Oncol. 2015 Mar 10; 33(8):937-43.
    View in: PubMed
    Score: 0.007
  55. Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells. Gynecol Oncol. 2015 Mar; 136(3):554-61.
    View in: PubMed
    Score: 0.007
  56. Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol. 2014 Oct 10; 32(29):3275-83.
    View in: PubMed
    Score: 0.007
  57. MicroRNAs in endometrial cancers from black and white patients. Am J Obstet Gynecol. 2015 Feb; 212(2):191.e1-10.
    View in: PubMed
    Score: 0.007
  58. Progesterone inhibits endometrial cancer invasiveness by inhibiting the TGF? pathway. Cancer Prev Res (Phila). 2014 Oct; 7(10):1045-55.
    View in: PubMed
    Score: 0.007
  59. A clinicopathologic study of vaginal intraepithelial neoplasia. Obstet Gynecol. 2013 Dec; 122(6):1223-30.
    View in: PubMed
    Score: 0.006
  60. Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes. Br J Cancer. 2014 Jan 07; 110(1):123-32.
    View in: PubMed
    Score: 0.006
  61. Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of Gynecologic Oncology Group (GOG) 182. Gynecol Oncol. 2013 Sep; 130(3):487-92.
    View in: PubMed
    Score: 0.006
  62. Progesterone enhances calcitriol antitumor activity by upregulating vitamin D receptor expression and promoting apoptosis in endometrial cancer cells. Cancer Prev Res (Phila). 2013 Jul; 6(7):731-43.
    View in: PubMed
    Score: 0.006
  63. Transcript expression in endometrial cancers from Black and White patients. Gynecol Oncol. 2013 Jul; 130(1):169-73.
    View in: PubMed
    Score: 0.006
  64. Mitochondrial proteomic analysis of cisplatin resistance in ovarian cancer. J Proteome Res. 2012 Sep 07; 11(9):4605-14.
    View in: PubMed
    Score: 0.006
  65. Should stage IIIC ovarian cancer be further stratified by intraperitoneal vs. retroperitoneal only disease?: a Gynecologic Oncology Group study. Gynecol Oncol. 2012 Jan; 124(1):53-8.
    View in: PubMed
    Score: 0.006
  66. Standardization of a sample preparation and analytical workflow for proteomics of archival endometrial cancer tissue. J Proteome Res. 2011 Nov 04; 10(11):5264-71.
    View in: PubMed
    Score: 0.006
  67. Racial disparities in recurrence among patients with early-stage endometrial cancer: is recurrence increased in black patients who receive estrogen replacement therapy? Cancer. 2008 Sep 15; 113(6):1431-7.
    View in: PubMed
    Score: 0.004
  68. A novel technique for the enrichment of primary ovarian cancer cells. Am J Obstet Gynecol. 2007 Nov; 197(5):507.e1-5.
    View in: PubMed
    Score: 0.004
  69. Outcomes of women with metachronous breast and ovarian carcinomas. Gynecol Oncol. 2006 Oct; 103(1):190-4.
    View in: PubMed
    Score: 0.004
  70. Enhanced killing of primary ovarian cancer by retargeting autologous cytokine-induced killer cells with bispecific antibodies: a preclinical study. Clin Cancer Res. 2006 Mar 15; 12(6):1859-67.
    View in: PubMed
    Score: 0.004
  71. Effect of excisional therapy and highly active antiretroviral therapy on cervical intraepithelial neoplasia in women infected with human immunodeficiency virus. Am J Obstet Gynecol. 2001 Mar; 184(4):538-43.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.